We soundly oppose President Trump’s budget outline, which would cut $6 billion from the National Institutes of Health (NIH). Reducing NIH’s funding by nearly 20 percent will devastate our nation’s already fragile federal research infrastructure and undercut a longstanding commitment to biomedical science that has fueled advances in cancer prevention, diagnosis, and treatment.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
The American Society of Clinical Oncology (ASCO) will release The State of Cancer Care in America: 2017 at a briefing on Capitol Hill on March 22. The report examines the current landscape of the cancer care delivery system in the United States, and outlines key opportunities and challenges facing cancer care providers and patients today.
On March 06, 2017, the United States House of Representatives released the American Healthcare Act, a bill to repeal and partly replace the Affordable Care Act (ACA).
On March 1, ASCO joined many national, state, and local organizations led by NDD United in sending a letter to Congress urging legislators to avoid making further reductions to nondefense discretionary or “NDD” government programs. NDD United formed in 2012 in response to the Budget Control Act of 2011, which established automatic across-the-board cuts to NDD programs. These NDD programs include medical research, public health, and other key programs critical to patients with cancer.
On Feb. 15, 2017, ASCO leadership and members of the ASCO Government Relations Committee (GRC) met with key federal agency and congressional committee staff to discuss ASCO's top policy priorities. Discussions focused on federal efforts to repeal and replace the Affordable Care Act (ACA), implementation of the Medicare Access and CHIP Reauthorization Act (MACRA) and the 21st Century Cures Act, among other matters.
With the new Congress and Administration in place, ASCO has been on Capitol Hill monitoring the issues that affect the cancer care community, and educating lawmakers on how best to serve Americans with cancer. In particular, ASCO is closely tracking efforts to repeal and replace the Affordable Care Act (ACA), the discussion on the future of Medicaid, and relevant cabinet appointments.
On January 3rd, the 115th Session of the U.S. Congress got underway. One of the first orders of business was appointing new leadership of Committees, including those with jurisdiction over issues of importance to cancer-related policy.